Adalimumab for rheumatoid arthritis

Bibliography

• LINDQVIST E, JONSSON K, SAXNE T, EBERHARDT K: Course of radiographic damage of 10 years in a cohort with early rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62:611-616.
   PubMed Web of Science ®Google Scholar
• WELSING PM, VAN GESTEL AM, SWINKELS HL, KIEMENEY LA, VAN RIEL PL: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. (2001) 44:2009-2017.
   PubMed Web of Science ®Google Scholar
• DROSOS AA, ALAMANOS I, VOULGARI PV et al.: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J. Rheumatol. (1997) 24:2129-2133.
   PubMed Web of Science ®Google Scholar
• UHLIG T, KVIEN TK, GLENNAS A, SMEDSTAD LM, FORRE O: The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J. Rheumatol. (1998) 25:1078-1084.
   PubMed Web of Science ®Google Scholar
• UHLIG T, KVIEN TK: Is rheumatoid arthritis disappearing? Ann. Rheum. Dis. (2005) 64:7-10.
   PubMed Web of Science ®Google Scholar
• ALAMANOS Y, DROSOS AA: Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. (2005) 4:130-136.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, MAINI RN, FELDMANN M: TNFα – a pivotal role in rheumatoid arthritis? Br. J. Rheumatol. (1992) 31:293-298.
   PubMedGoogle Scholar
• FIRESTEIN GS: The immunopathogenesis of rheumatoid arthritis. Curr. Opin. Rheumatol. (1991) 3:398-406.
   PubMed Web of Science ®Google Scholar
• CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
   PubMed Web of Science ®Google Scholar
• DROSOS AA: Newer immunosuppressive drugs: their potential role in rheumatoid arthritis. Drugs (2002) 62:891-907.
   PubMed Web of Science ®Google Scholar
• DROSOS AA: Methotrexate intolerance in elderly rheumatoid arthritis patients: what are the alternatives? Drug Aging (2003) 20:723-736.
   PubMed Web of Science ®Google Scholar
• KIRWAN JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. (1995) 333:142-146.
   PubMed Web of Science ®Google Scholar
• SVENSSON B, BOONEN A, ALBERTSSON K, VAN DER HEIJDE D, KELLER C, HAFSTROM I: Low-dose prednisone in addition to the initial disease-modifying antirheumatic drug in patients with early rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. (2005) 52:3360-3370.
   PubMed Web of Science ®Google Scholar
• PAPADOPOULOS NG, ALAMANOS Y, PAPADOPOULOS IA, TSIFETAKI N, VOULGARI PV, DROSOS AA: Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J. Rheumatol. (2002) 29:261-266.
   PubMed Web of Science ®Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 353:259-266.
   PubMed Web of Science ®Google Scholar
• DROSOS AA, VOULGARI PV, KATSARAKI A, ZIKOU AK: Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol. Int. (2000) 19:113-118.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, REDA D, HENDERSON W et al.: Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J. Rheumatol. (1999) 26:2123-2130.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337:141-147.
   PubMed Web of Science ®Google Scholar
• BANG LM, KEATING GM: Adalimumab: a review of its use in rheumatoid arthritis. Biodrugs (2004) 18:121-139.
   PubMed Web of Science ®Google Scholar
• ABBOTT: Humira® [package insert]. Abbott, Abbott Park, IL, USA (2006).
   Google Scholar
• GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. (2005) 353:1114-1123.
   PubMed Web of Science ®Google Scholar
• EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350:2572-2581.
   PubMed Web of Science ®Google Scholar
• SANTORA LC, KRULL IS, GRANT K: Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal. Biochem. (1999) 275:98-108.
   PubMed Web of Science ®Google Scholar
• BARRERA P, JOOSTEN LA, DEN BROEDER AA, VAN DE PUTTE LB, VAN RIEL PL, VAN DEN BERG WB: Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2001) 60:660-669.
   PubMed Web of Science ®Google Scholar
• DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilabe turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61:311-318.
   PubMed Web of Science ®Google Scholar
• AWNI WM, CASCELLA P, OLEKA NA et al.: Steady-state pharmacokinetics (PK) of adalimumab (HumiraTM, Abbott) following 40 mg subcutaneous (SC) injection every other week (EOW) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy [abstract n 259]. Arthritis Rheum. (2003) 48(9 Suppl.):S140.
   Google Scholar
• DEN BROEDER A, VAN DE PUTTE L, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:2288-2298.
   PubMed Web of Science ®Google Scholar
• RAU R, SANDER O, DEN BROEDER A et al.: Long term efficacy and tolerability of multiple iv doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41(Suppl.):S55.
   Google Scholar
• SCHATTENKIRCHNER M, KRUGER K, SANDER O et al.: Efficacy and tolerability of weekly subcutaneous injections of the full human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. (1998) 41(Suppl.):S57.
   Google Scholar
• FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant stantdard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. (2003) 30:2563-2571.
   PubMed Web of Science ®Google Scholar
• VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. (2004) 63:508-516.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50:1400-1411.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. (2006) 54:26-37.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE, KAVANAUGH AF, CHARTASH EK, SEGURADO OG: Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4-year extended study. Ann. Rheum. Dis. (2006) 65:753-759.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
   PubMed Web of Science ®Google Scholar
• VAN GESTEL AM, ANDERSON JJ, VAN RIEL PL et al.: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology). Rheumatology (1999) 26:705-711.
   Web of Science ®Google Scholar
• PREVOO ML, VAN’T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. (1995) 38:44-48.
   PubMed Web of Science ®Google Scholar
• WARE JE JR, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care (1992) 30:473-483.
   PubMed Web of Science ®Google Scholar
• FRIES JF, SPITZ PW, YOUNG DY: The dimentions of health outcomes: the health assessment questionnaire, disability and pain scales. J. Rheumatol. (1982) 9:789-793.
   PubMed Web of Science ®Google Scholar
• WEBSTER K, CELLA D, YOST K: The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual. Life Outcomes (2003) 1:79.
   PubMedGoogle Scholar
• CELLA D, WEBSTER K: Linking outcomes management to quality-of-life measurement. Oncology (Williston Park) (1997) 11:232.
   PubMedGoogle Scholar
• SHARP JT, LIDSKY MD, COLLINS LC, MORELAND J: Methods of scoring the progression of radiographic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. (1971) 14:706-720.
   PubMed Web of Science ®Google Scholar
• SHARP JT, YOUNG DY, BLUHM GB et al.: How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. (1985) 28:1326-1335.
   PubMed Web of Science ®Google Scholar
• BURMESTER GR, MONTEAGUDO SAEZ I, MAILAISE M, CANAS DA SILVA J, WEBBER D, KUPPER H: Adalimumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year results of ReAct study. Arthritis Rheum. (2005) 52(Suppl.):S541.
   Google Scholar
• BOMBARDIERI S, TZIOUFAS AG, MCKENNA F, OZER U, HUPPER Η: Adalimumab (Humira®) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life clinical setting. Arthritis Rheum. (2005) 52(Suppl.):S144.
   PubMed Web of Science ®Google Scholar
• WICK MC, ERNESTAM S, LINDBLAD S, BRATT J, KLARESKOG L, VAN VOLLENHOVEN RF: Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand. J. Rheumatol. (2005) 34:353-358.
   PubMed Web of Science ®Google Scholar
• GOMEZ-REINO JJ, CARMONA L: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. BIOBADASER GROUP. Arthritis Res. Ther. (2006) 8:R29.
   PubMed Web of Science ®Google Scholar
• NIKAS SN, VOULGARI PV, ALAMANOS Y et al.: The efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann. Rheum. Dis. (2006) 65:257-260.
   PubMed Web of Science ®Google Scholar
• ZIKOU AK, ARGYROPOULOU MI, VOULGARI PV et al.: Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J. Rheumatol. (2006) 33:219-223.
   PubMed Web of Science ®Google Scholar
• ROUX CH, BROCQ O, BREUIL V, ALBERT C, EULLER-ZIEGLER L: Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (2006) 45:1294-1297.
   PubMed Web of Science ®Google Scholar
• GILES JT, BARTLETT SJ, GELBER AC et al.: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. (2006) 55:333-337.
   PubMed Web of Science ®Google Scholar
• CARMONA L, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. (2005) 52:1766-1772.
   PubMed Web of Science ®Google Scholar
• HYRICH KL, SYMMONS DP, WATSON KD, SILMAN AJ: Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. British Society, for Rheumatology Biologics Register. Arthritis Rheum. (2006) 54:2701-2702.
   PubMed Web of Science ®Google Scholar
• BEUTHIEN W, MELLINGHOFF HU, VON KEMPIS J: Skin reaction to adalimumab. Arthritis Rheum. (2004) 50:1690-1692.
   PubMed Web of Science ®Google Scholar
• NIKAS SN, VOULGARI PV, DROSOS AA: Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin. Rheumatol. (2006):1-2.
   PubMed Web of Science ®Google Scholar
• SCHIFF M, VAN DE PUTTE LB, LREEDVELD FC et al.: Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract THU0246]. Ann. Rheum. Dis. (2003) 62(Suppl. 1):184.
   Google Scholar
• SCHIFF MH, BURMESTER GR, KENT JM et al.: Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65:889-894.
   PubMed Web of Science ®Google Scholar
• DE RYCKE L, KRUITHOF E, VAN DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. (2003) 48:1015-1023.
   PubMed Web of Science ®Google Scholar
• ERIKSSON C, ENGSTRAND S, SUNDQVIST KG, RANTAPAA-DAHLQVIST S: Antibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. (2005) 64:403-407.
   PubMed Web of Science ®Google Scholar
• ALESSANDRI C, BOMBARDIERI M, PAPA N et al.: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. (2004) 63:1218-1221.
   PubMed Web of Science ®Google Scholar
• ATZENI F, SARZI-PUTTINI P, DELL’ ACQUA D et al.: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther. (2005) 8:R3.
   Google Scholar